EGFR and non-small cell lung carcinoma: In current history, great strides have been made in the treatment of advanced non-small-cell lung cancer (NSCLC), and there is a consensus that epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy is preferred for patients who are EGFR-positive.